An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Improved disease-free survival seen among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery.

Is there any difference in efficacy with Keytruda (pembrolizumab) on three-week intervals versus six-week intervals? No. In ...

Renal cancer, also known as kidney cancer, is a disease where malignant (cancer) cells form in the tissues of the kidneys. Smoking, obesity, hypertension, and chronic kidney disease contribute to ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

In monotherapy, BT-001 induced tumor shrinkage in 2 of 6 injected lesions.In combination with KEYTRUDA® (pembrolizumab), partial responses were observed in 2 of 6 patients who failed previous ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") , a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for its breast ...

Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Compan ...

Today, the industry leader in wellness technology, Therabody, added five new innovations and four limited editions of bestselling products to their ecosystem of science-backed solutions. The latest ...

With the recent wrapping up of the World Cancer Congress 2024 in Geneva, Switzerland, and the European Society for Medical ...